(Date:12/1/2008).../ -- Vical Incorporated (Nasdaq: VICL ) announce...yment from Merck & Co., Inc. based on Merck,s ...an investigational plasmid DNA (pDNA) cancer vacci...gene delivery technology and encodes human telomer...bject of separate license agreement. , , "T...
(Date:11/27/2008)...ymphoblastic leukemia relapse cases arise from a c... , MEMPHIS, Tenn., Nov. 27 /PRNewswire-USNewswi...Hospital have identified distinctive genetic chang...hoblastic leukemia (ALL) that cause relapse. The f...r ALL relapse in children and, ultimately, in adul...
(Date:11/25/2008)...Newswire/ -- Kleinert Kutz and University of Loui...d transplant on Messina, New York resident, Jan "E...d Care Center on Monday, November 24. The innovat...shortly after 9 p.m. in a record nine hours. , ...h/20081125/DC48555-a ) , (Photo: http://www.n...
(Date:11/25/2008)... to Assess Survival of Patients Receiving Litx ver...patocellular Carcinoma , , BELLEVUE, Wash.,...Inc. (LSO) today announced the completion of enrol...Infusion Therapy(TM) (Litx(TM)) as a treatment for... known as hepatoma or primary liver cancer. , ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2062 1Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2062 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2062 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2062 4Clot Busting Treatment Improves Bleeding Stroke Outcomes 19289 1Clot Busting Treatment Improves Bleeding Stroke Outcomes 19289 2Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin 19286 1Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin 19286 2Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin 19286 3Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin 19286 4Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin 19286 5FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 1FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 2FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 3FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 4FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 5FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 6FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 7FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 8FDA Approves AstraZenecas Seroquel 28R 29 for Maintenance Treatment in Bipolar Disorder 19283 9...007 – Intercell AG (VSE,“ICLL”)...& Co., Inc. on the results of a Phase I study ...rs comparing safety and,immunogenicity of differen...he Staphylococcus aureus vaccine is based on a con...uo;s Antigen Identification,Program (AIP®) and...
...2007 /PRNewswire-FirstCall/ -- A total,of 20 oral ...Schering-Plough,s hepatitis products, including PE... (ribavirin, USP) combination,therapy for chronic ...previr (SCH 503034), the company,s investigational... clinical development, will,be presented by leadin...
Other Medicine Technology:Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 2Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 2Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 4Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 5Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 6Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 7...t is a clinical chemistry assay that detects Ische...obalt binding capacity of albumin in a patient ser...A is produced when circulating albumin comes in co...chemia, the N-terminus of albumin is altered throu...
...t is a clinical chemistry assay that detects Ische...obalt binding capacity of albumin in a patient ser...A is produced when circulating albumin comes in co...chemia, the N-terminus of albumin is altered throu...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl
...t is a clinical chemistry assay that detects Ische...obalt binding capacity of albumin in a patient ser...A is produced when circulating albumin comes in co...chemia, the N-terminus of albumin is altered throu...
Medicine Products: